Other languages Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
26.33 ^USD	+3.25%		+0.30%	-21.96%

03-13	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
03-13	Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Los bancos occidentales advierten de los riesgos del plan de la UE para usar los activos rusos	03-22
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	03-13
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	03-13
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing	03-08
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	02-29
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	02-29
Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy	02-15
Pacira BioSciences Awarded Group Purchasing Agreement with Premier	02-07
Pacira BioSciences Receives Brand Pharmaceuticals Agreement With Premier, Inc	02-07
Pacira BioSciences Says Preliminary Data Show 2023 Sales Rose 1.2% From Year Earlier, Topping Consensus	01-04
Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024	12-21
Pacira Biosciences, Inc. Appoints Frank D. Lee as Member of the Board, Effective January 2, 2024	12-21
Pacira BioSciences Names Frank D. Lee CEO, Board Member	12-21
Pacira BioSciences Says US FDA Approves Exparel Application for Two Additional Nerve Block Indications	11-10
Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications	11-10
Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023	11-02
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02
Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors	23-10-10
Pacira BioSciences Chief Executive to Retire	23-09-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Other languages

Filters